Is The Bad News Priced Into Nike Stock Now?
Despite its dominance in the athletic shoe and apparel industry,…
Buy
66
DERM Quote, Financials, Valuation and Earnings
Last price:
$6.57
Seasonality move
:
24.77%
Day range:
$6.00 - $6.65
52-week range:
$3.20 - $6.89
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.27x
P/B ratio:
7.18x
Volume:
83.6K
Avg. volume:
61.2K
1-year change:
83.53%
Market cap:
$144.2M
Revenue:
$56.1M
EPS (TTM):
-$0.74
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DERM
Journey Medical
|
$12.1M | -- | -7.49% | -- | $9.88 |
|
FBIO
Fortress Biotech
|
$10.4M | -$0.44 | -9.13% | -41.51% | $15.33 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.24 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -100% | -67.93% | $7.00 |
|
TOVX
Theriva Biologics
|
-- | -$5.50 | -- | -8.25% | $6.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DERM
Journey Medical
|
$6.24 | $9.88 | $144.2M | -- | $0.00 | 0% | 2.27x |
|
FBIO
Fortress Biotech
|
$1.53 | $15.33 | $42.2M | -- | $0.00 | 0% | 0.30x |
|
NBY
NovaBay Pharmaceuticals
|
$0.57 | $0.85 | $2.8M | -- | $0.00 | 0% | 0.06x |
|
OGEN
Oragenics
|
$0.20 | $1.00 | $4.3M | -- | $0.00 | 0% | 1.24x |
|
PTN
Palatin Technologies
|
$0.54 | $7.00 | $14M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics
|
$1.18 | $6.00 | $3.3M | -- | $0.00 | 0% | 0.63x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DERM
Journey Medical
|
55.35% | 1.457 | 30.46% | 0.87x |
|
FBIO
Fortress Biotech
|
71.75% | 0.739 | 900.37% | 0.99x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.451 | 1.51% | 0.75x |
|
OGEN
Oragenics
|
-- | 3.461 | -- | -- |
|
PTN
Palatin Technologies
|
-- | 0.220 | -- | 0.99x |
|
TOVX
Theriva Biologics
|
-- | -1.635 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DERM
Journey Medical
|
$11.4M | -$2.3M | -43.33% | -97.05% | 17.72% | $2.2M |
|
FBIO
Fortress Biotech
|
$9.3M | -$22.1M | -94.06% | -- | -166.72% | -$20.1M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
OGEN
Oragenics
|
-- | -$3.4M | -- | -- | -- | -$2M |
|
PTN
Palatin Technologies
|
-- | -$5.1M | -- | -- | -2356.3% | -$4.8M |
|
TOVX
Theriva Biologics
|
-- | -$4.6M | -- | -- | -- | -$4.7M |
Journey Medical vs. Competitors
-
Which has Higher Returns DERM or FBIO?
Fortress Biotech has a net margin of 11.17% compared to Journey Medical's net margin of -87.96%. Journey Medical's return on equity of -97.05% beat Fortress Biotech's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical83.58% $0.08 $44.9M FBIOFortress Biotech63.87% -$0.76 $41M -
What do Analysts Say About DERM or FBIO?
Journey Medical has a consensus price target of $9.88, signalling upside risk potential of 58.25%. On the other hand Fortress Biotech has an analysts' consensus of $15.33 which suggests that it could grow by 852.38%. Given that Fortress Biotech has higher upside potential than Journey Medical, analysts believe Fortress Biotech is more attractive than Journey Medical.
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical3 0 0 FBIOFortress Biotech1 0 0 -
Is DERM or FBIO More Risky?
Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.825, suggesting its more volatile than the S&P 500 by 82.547%.
-
Which is a Better Dividend Stock DERM or FBIO?
Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Fortress Biotech pays out -14.46% of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or FBIO?
Journey Medical quarterly revenues are $13.6M, which are smaller than Fortress Biotech quarterly revenues of $14.6M. Journey Medical's net income of $1.5M is higher than Fortress Biotech's net income of -$12.9M. Notably, Journey Medical's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.27x versus 0.30x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical2.27x -- $13.6M $1.5M FBIOFortress Biotech0.30x -- $14.6M -$12.9M
-
Which has Higher Returns DERM or NBY?
NovaBay Pharmaceuticals has a net margin of 11.17% compared to Journey Medical's net margin of -49.65%. Journey Medical's return on equity of -97.05% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical83.58% $0.08 $44.9M NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About DERM or NBY?
Journey Medical has a consensus price target of $9.88, signalling upside risk potential of 58.25%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 48.6%. Given that Journey Medical has higher upside potential than NovaBay Pharmaceuticals, analysts believe Journey Medical is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical3 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is DERM or NBY More Risky?
Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.
-
Which is a Better Dividend Stock DERM or NBY?
Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or NBY?
Journey Medical quarterly revenues are $13.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Journey Medical's net income of $1.5M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Journey Medical's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.27x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical2.27x -- $13.6M $1.5M NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M
-
Which has Higher Returns DERM or OGEN?
Oragenics has a net margin of 11.17% compared to Journey Medical's net margin of --. Journey Medical's return on equity of -97.05% beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical83.58% $0.08 $44.9M OGENOragenics-- -$0.27 -- -
What do Analysts Say About DERM or OGEN?
Journey Medical has a consensus price target of $9.88, signalling upside risk potential of 58.25%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 400.25%. Given that Oragenics has higher upside potential than Journey Medical, analysts believe Oragenics is more attractive than Journey Medical.
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical3 0 0 OGENOragenics0 1 0 -
Is DERM or OGEN More Risky?
Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.868, suggesting its less volatile than the S&P 500 by 13.16%.
-
Which is a Better Dividend Stock DERM or OGEN?
Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or OGEN?
Journey Medical quarterly revenues are $13.6M, which are larger than Oragenics quarterly revenues of --. Journey Medical's net income of $1.5M is higher than Oragenics's net income of -$3.3M. Notably, Journey Medical's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.27x versus 1.24x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical2.27x -- $13.6M $1.5M OGENOragenics1.24x -- -- -$3.3M
-
Which has Higher Returns DERM or PTN?
Palatin Technologies has a net margin of 11.17% compared to Journey Medical's net margin of -2357.27%. Journey Medical's return on equity of -97.05% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical83.58% $0.08 $44.9M PTNPalatin Technologies-- -$0.12 -$111.5K -
What do Analysts Say About DERM or PTN?
Journey Medical has a consensus price target of $9.88, signalling upside risk potential of 58.25%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1200.63%. Given that Palatin Technologies has higher upside potential than Journey Medical, analysts believe Palatin Technologies is more attractive than Journey Medical.
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical3 0 0 PTNPalatin Technologies0 0 0 -
Is DERM or PTN More Risky?
Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.
-
Which is a Better Dividend Stock DERM or PTN?
Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or PTN?
Journey Medical quarterly revenues are $13.6M, which are larger than Palatin Technologies quarterly revenues of $350K. Journey Medical's net income of $1.5M is higher than Palatin Technologies's net income of -$2.4M. Notably, Journey Medical's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.27x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical2.27x -- $13.6M $1.5M PTNPalatin Technologies-- -- $350K -$2.4M
-
Which has Higher Returns DERM or TOVX?
Theriva Biologics has a net margin of 11.17% compared to Journey Medical's net margin of --. Journey Medical's return on equity of -97.05% beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DERMJourney Medical83.58% $0.08 $44.9M TOVXTheriva Biologics-- -$1.60 -- -
What do Analysts Say About DERM or TOVX?
Journey Medical has a consensus price target of $9.88, signalling upside risk potential of 58.25%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 408.48%. Given that Theriva Biologics has higher upside potential than Journey Medical, analysts believe Theriva Biologics is more attractive than Journey Medical.
Company Buy Ratings Hold Ratings Sell Ratings DERMJourney Medical3 0 0 TOVXTheriva Biologics0 0 0 -
Is DERM or TOVX More Risky?
Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.
-
Which is a Better Dividend Stock DERM or TOVX?
Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DERM or TOVX?
Journey Medical quarterly revenues are $13.6M, which are larger than Theriva Biologics quarterly revenues of --. Journey Medical's net income of $1.5M is higher than Theriva Biologics's net income of -$4.4M. Notably, Journey Medical's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.27x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DERMJourney Medical2.27x -- $13.6M $1.5M TOVXTheriva Biologics0.63x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is LUV Stock a Buy, Sell or Hold?
Southwest Airlines (NYSE:LUV) is one of America’s major air transportation…
Should I Buy Alcoa Stock?
Alcoa (AA) finds itself in an interesting position in early…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 33x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
44
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
43
MNPR alert for Apr 3
Monopar Therapeutics [MNPR] is down 10.04% over the past day.
Buy
75
BKTI alert for Apr 4
BK Technologies [BKTI] is down 7.68% over the past day.
Sell
34
SWTX alert for Apr 3
SpringWorks Therapeutics [SWTX] is down 7.29% over the past day.
